Salvianolic Acid B Administration Attenuate Bone Loss in Ovariectomy Induced Rat Model

Yuanyuan Liu,Haili Shen
DOI: https://doi.org/10.3923/ijp.2018.866.872
2018-01-01
International Journal of Pharmacology
Abstract:Background and Objective: Osteoporosis is a chronic progressive skeletal disorder characterized by low Bone Mass Density (BMD) and bone quality. This study was aimed to access the anti-osteoporotic effects of salvianolic acid B (SAB-B) against ovariectomy-induced in rat model. Materials and Methods: Forty female (n = 40) rats were randomly chosen and divided into four groups as sham-operated control (underwent bilateral laparotomy; sham group, n=10), whereas rats underwent laparotomy followed by bilateral ovariectomy (ovariectomy model group; OVX, n= 10). Whereas, OVX underwent rats were orally supplemented with either 20 or 40 mg kg(-1) of SAB-B (OVX+20 or 40 mg kg(-1) SAB-B group; n= 10) for 12 weeks after 4 weeks of OVX. Statistical difference between the experimental groups were analyzed by student t-test using SPSS software at p < 0.05. Results: Treatment with SAB-B (20 or 40 mg kg(-1)), substantially increased the body weight than OVX rats. A pronounced elevation in the levels of Bone Mineral Density/Content(BMD/BMC)and body weight were observed in SAB-B treated group as compared to OVX group. Bone markers like deoxypyridinoline, alkaline phosphatase and osteocalcin as well as inflammatory markers like IL-1 beta, IL-6, TNF-alpha concentrations were significantly abolished after 12 weeks of administration with SAB-A in OVX rats. Furthermore, the bone biomechanical stability was notably improved upon supplementation with SAB-B. Conclusion: Both SAB-B 20 and 40 mg kg(-1) treatment exhibit potent anti-osteoporotic activity, nevertheless SAB-B 40 showed superior anti-osteoporotic activity than SAB-B 20. Therefore, SAB-B would be recommended for treating post-menopausal osteoporosis with other standard drugs.
What problem does this paper attempt to address?